Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer

This article was originally published in The Tan Sheet

Executive Summary

Aleve pain reliever sales advanced 27.5% to $302.3 mil. (E1=$1.33) in 2006 (ended Dec. 31), Bayer announces March 15. One-A-Day achieved sales growth of 5.1% to $165.1 mil. and Alka-Seltzer revenues increased 6.3% to $101 mil. for the year, firm adds. The brands helped drive sales of Bayer's Consumer Health Consumer Care Division, which jumped 7.5% to $3.37 bil. for the year, the company reports, noting it doubled sales of its OTC pharmaceuticals franchise during the year. The Consumer Health segment had net sales of $5.66 bil., representing growth of 8.1%. The company is continuing expansion of the Consumer Health division abroad, particularly in China, with the recent purchase of OTC company Topsun's cough/cold portfolio (1"The Tan Sheet" Oct. 30, 2006, p. 9). The HealthCare group's net sales grew 46.6% to $15.62 bil., and earnings before interest, taxes, depreciation and amortization before special items soared 75.7% to $3.48 bil. Bayer is targeting underlying EBITDA margin growth of about 27% in HealthCare in 2009...

You may also be interested in...



Bayer Increases Chinese Presence With Topsun Cough/Cold Buy

Bayer expects its purchase of Topsun Science & Technology's nonprescription cough and cold portfolio to "substantially increase Bayer Consumer Care's presence in China, one of the fastest growing OTC markets in the world," the firm states Oct. 25

Health And Wellness Trademark Review 14 January, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.

Topics

UsernamePublicRestriction

Register

PS100327

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel